Lupin launches Amabelz tablets in US market

NEW DELHI: Drug major Lupin today said it has launched Amabelz tablets, used in prevention of postmenopausal osteoporosis, in the American market after getting approval from the US health regulator.

Lupin Pharmaceuticals Inc, a subsidiary of the company, has launched Amabelz tablets, a generic version of Amneal Pharmaceuticals' Activella tablets in the US, Lupin said in a statement.

The company's product is indicated in a woman with a uterus for treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis.

According to IMS MAT sales data, Activella had US sales of $91.1 million.

Shares of Lupin ended 1.37 per cent down at Rs 1,440.20 on BSE.